Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation on April 8, 2015. The filing addresses Item 5.02 regarding the approval of compensatory arrangements for certain named executive officers by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of new equity-based compensation awards.
Material Changes and Compensation Details
On April 8, 2015, the Company approved performance-based stock options and restricted stock units (RSUs) for four executive officers under the 2014 Long-Term Incentive Plan. All awards have a 10-year term, and stock options carry a strike price of $8.07.
- Phillip Chan, MD, PhD (President and CEO): 70,000 stock options and 130,000 RSUs.
- Vincent Capponi (COO): 66,000 stock options and 125,000 RSUs.
- Kathleen Bloch (CFO): 56,000 stock options and 110,000 RSUs.
- Robert Bartlett, MD (CMO): 20,000 stock options and 30,000 RSUs.
Stock Option Vesting Milestones:
- 45% upon achieving 2015 budgeted revenues without exceeding budgeted operating expenses.
- 30% upon achievement of multiple clinical trial objectives in 2015.
- 15% upon demonstration of reasonable progress in U.S. regulatory approval of a product.
- 10% upon achievement of one or more new major strategic partnerships.
RSU Settlement: Restricted stock units will be settled into common stock upon vesting only in the event of a "Change In Control" as defined in the Company's 2014 Long-Term Incentive Plan.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, general outlook commentary, or specific risk factors beyond the performance conditions attached to the executive compensation. The vesting conditions imply management's focus on 2015 revenue targets, clinical trial progress, regulatory approval, and strategic partnerships.
Investor Verification Checklist
- Verify the current stock price relative to the $8.07 strike price of the newly granted options.
- Review the Company's 2015 budgeted revenue and operating expense targets to assess the feasibility of the 45% vesting milestone.
- Monitor upcoming clinical trial results and regulatory filings to evaluate the 30% and 15% vesting milestones.
- Confirm the specific definition of "Change In Control" in the 2014 Long-Term Incentive Plan to understand the liquidity event required for RSU settlement.